SCHEMBL21490482

SCHEMBL21490482

Cc1ccc(S(=O)(=O)n2c(C)cc3c(Cl)c([N+](=O)[O-])cnc32)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.40
LMNA P02545 5/20 0.39
PTGDR2 Q9Y5Y4 2/20 0.39
KDM4E B2RXH2 1/20 0.39
TSHR P16473 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PAX8 Q06710 1/20 0.39
DCTPP1 Q9H773 1/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPT P10636 2/20 0.39
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38
PKM P14618 1/20 0.38
NPC1 O15118 1/20 0.38
VCAM1 P19320 2/20 0.38
MAPK1 P28482 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ATIC P31939 1/20 0.37
HSP90AA1 P07900 1/20 0.37
CXCR5 P32302 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20535992 0.81 ABL1 (0.45) HSD11B1LMNAPTGDR2KDM4ETSHR
SCHEMBL23120015 0.81 L3MBTL1 (0.46) HSD11B1LMNAL3MBTL1PAX8ALDH1A1
SCHEMBL29486806 0.79 DCTPP1 (0.42) PTGDR2DCTPP1ALDH1A1KMT2AMEN1
SCHEMBL24164979 0.79 DCTPP1 (0.42) PTGDR2DCTPP1ALDH1A1KMT2AMEN1
SCHEMBL21490844 0.75 PTGDR2 (0.46) HSD11B1LMNAPTGDR2KDM4EL3MBTL1
SCHEMBL15408335 0.75 LMNA (0.41) HSD11B1LMNAPTGDR2KDM4ETSHR
SCHEMBL24165525 0.74 DCTPP1 (0.39) LMNAPTGDR2DCTPP1ALDH1A1MAPT
SCHEMBL17535141 0.73 ALDH3A1 (0.39) HSD11B1LMNAPTGDR2KDM4EL3MBTL1
SCHEMBL1356567 0.73 HTT (0.39) HSD11B1LMNAPTGDR2KDM4EL3MBTL1
SCHEMBL15426826 0.71 PTGDR2 (0.43) LMNAPTGDR2KDM4ETSHRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827638-B2 Imidazopyrrolopyridine as inhibitors of the JAK family of kinases JANSSEN PHARMACEUTICA NV (BE) 2023-11-28 US disclosed
EP-3555096-B1 IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES JANSSEN PHARMACEUTICA NV (BE) 2022-11-23 EP disclosed
CN-114685505-A Imidazopyrrolopyridines as JAK family kinase inhibitors 詹森药业有限公司 2022-07-01 CN disclosed
CN-110312719-B Imidazopyrrolopyridines as JAK family kinase inhibitors 詹森药业有限公司 2022-04-15 CN disclosed
US-20210206768-A1 IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES JANSSEN PHARMACEUTICA NV (BE) 2021-07-08 US disclosed
US-10981911-B2 Imidazopyrrolopyridine as inhibitors of the JAK family of kinases JANSSEN PHARMACEUTICA NV (BE) 2021-04-20 US disclosed
US-20190322665-A1 IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES JANSSEN PHARMACEUTICA NV (BE) 2019-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827638-B2 Imidazopyrrolopyridine as inhibitors of the JAK family of kinases JAK1, JAK2, JAK3 HSD11B1 4427/4885LMNA 4330/4885PTGDR2 748/4885
US-20210206768-A1 IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES JAK1, JAK2, JAK3 HSD11B1 4427/4885LMNA 4330/4885PTGDR2 748/4885
US-10981911-B2 Imidazopyrrolopyridine as inhibitors of the JAK family of kinases JAK1, JAK2, JAK3 HSD11B1 4427/4885LMNA 4330/4885PTGDR2 748/4885
US-20190322665-A1 IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES JAK1, JAK2, JAK3 HSD11B1 4427/4885LMNA 4330/4885PTGDR2 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.